BioSpace News Archive

Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatment, today reported preliminary gross sales results of $7.0 million for the third quarter ended September 30, 2019 compared to $6.2 million for the second quarter ended June 30, 2019 based on total boxes shipped.

AMAG Pharmaceuticals, Inc. announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials and its voluntary open-label one year extension studies were published in Obstetrics & Gynecology These publications are currently available online and will appear in the November print issue.

Allwell from Superior HealthPlan has earned 4.5 of 5.0 stars from the Centers for Medicare and Medicaid Services (CMS) in their annual Star Ratings report.

Continuing its pursuit to establish premier events for baseline transactions of hemp and CBD (cannabidiol) products, Southern Hemp Marketplace (SHM), LLC., today announced that Eurofins Quality Trait Analysis (QTA) will join its first-ever International Hemp Auction and Market (IHAM) as an official lab analysis partner.

Sophisticated image analyses and other tests will characterize neurological and behavioral outcomes for infants exposed to opioids in the womb

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present at the 5th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET.

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will announce its financial results for the third quarter ended September 31, 2019 and hold its Third Quarter 2019 Earnings Conference Call on Tuesday, November 12, 2019 at 8:30 a.m. EDT

Eyevensys a private, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco

We are increasingly concerned by the substantial rise of vaping among Canadian youth. As nicotine in any form is highly addictive, non-smokers who vape products containing nicotine are at risk of going on to use tobacco products such as cigarettes.

Kangpu Biopharmaceuticals announced that it has successfully completed a first-in-human phase I single ascending dose clinical study of KPG-818 conducted in the United States.